
|Articles|December 12, 2012
Zytiga now available for late-stage prostate cancer
FDA expanded the approved use of abiraterone acetate (Zytiga, Janssen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Oral Semaglutide Show Promise as New Benchmark for Diabetes Care, Cardiovascular Protection
2
Limited Clinical Data Impact Cannabis Integration Into Standard Care | ASHP Midyear 2025
3
Opioid Overdose Deaths Fall by 34% in 2025 | ASHP Midyear 2025
4
Delgocitinib Improves Patients’ Chronic Hand Eczema
5




























































































































